Home > Cardiology > Heart polypill cuts cardiovascular disease risks by 21% over placebo in primary prevention trial

Heart polypill cuts cardiovascular disease risks by 21% over placebo in primary prevention trial


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
New England Journal of Medicine
Conference
AHA 2020
Reuters Health - 13/11/2020 - A new test of a multi-drug pill containing a statin and three blood pressure medicines shows that long-term use can lower cardiovascular disease risks for people with no previous history of heart disease or stroke by 21%. Adding low-dose aspirin to the mix cuts the odds by 31%. The pill used in the 5,713-patient TIPS-3 study contained simvastatin, atenolol, hydrochlorothiazide and ramipril. For the primary outcome of a major cardiovascular event plus heart failure, resuscitated cardiac arrest or arterial revascularization, the rate after a mean follow-up of 4.6 years was 4.4% in the polypill group and 5.5% among placebo recipients (95% confidence interval of 0.63 to 1.00). When 75 mg of aspirin was added to the daily treatment, the rates were 4.1% with the polypill and 5.8% in the control group (0.50 to 0.97). "There was a similar effect on death from cardiovascular causes, myocardial infarction or stroke," said the...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on